Clinical trials: Obstructive Chronic Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Balance Training in Patients With Chronic Obstructive Pulmonary Disease (COPD)
A growing body of evidence suggests that individuals with chronic lung disease have important deficits in balance control that may be associated with an increased risk of falls.
- Trial name
- NCT01424098
- Testing
- Balance training program
- Where
- Canada
- Volunteers
- 46 people
- Sponsor
- Roger Goldstein
Gingivitis; Chronic, Oxidative Stress
Efficacy of Green and White Tea Extract Mouthwashes in the Management of Plaque-induced Gingivitis: A Clinical and Biochemical Study
Background and objective: Tea is the second most consumed drink in the world after water. Gingivitis is among the most common infectious diseases.
- Conditions
- Gingivitis; Chronic, Oxidative Stress, Inflammation
- Trial name
- NCT05861206
- Testing
- GT-MW group (5% Green tea), WT-MW group (5% White tea),EO-MW group (Listerine mouthrinse), CHX-MW group (0.12% CHX, as a positive control group)
- Where
- Turkey (Türkiye)
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Yağmur Saraç Gül
Chronic Obstructive Pulmonary Disease
High Frequency Chest Wall Oscillation in Chronic Obstructive Pulmonary Disease (COPD)
Patients with Chronic obstructive pulmonary disease (COPD) tend to have cough, excess mucus production and breathlessness as cardinal features.
- Trial name
- NCT00863616
- Testing
- HFCWO - SmartVest
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- East and North Hertfordshire NHS Trust
Pulmonary Disease, Chronic Obstructive
Safety, Toleration and Efficacy of Single Inhaled Doses of PF-00610355 in Chronic Obstructive Pulmonary (COPD) Patients.
This study will look at the pharmacokinetics, safety, toleration and efficacy of PF-00610355 in the chronic obstructive pulmonary disease (COPD) population.
- Trial name
- A7881010 (NCT00783406)
- Testing
- PF-00610355
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Pfizer
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of Nemiralisib
Nemiralisib is a potent anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease (COPD) and other inflammatory lung diseases.
- Trial name
- NCT03398421
- Testing
- Nemiralisib, Itraconazole
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
Effect of Supplementary Vitamins on Oxidant Gene Expression in the Lungs of Healthy Smokers
Smoking damages the airway epithelium. The major mechanism by which this is done is by molecules called free radicals. Our body attempts to deal with these damaging molecules in two ways.
- Trial name
- NCT00565214
- Testing
- Group 1, Group 2
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
COPD
Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients
The goal of this clinical trial is to compare the acute bronchodilator effect of pMDI formed Ipratropium / Levosalbutamol 20 mcg / 50 mcg fixed dose combination or pMDI formed Salbutamol 100 mcg Inhaler and Ipratropium 20 mcg…
- Trial name
- NCT06040424
- Testing
- Ipratropium / Levosalbutamol Fixed Dose Combination, Ipratropium + Levosalbutamol Free Dose Combination
- Where
- Turkey (Türkiye)
- Volunteers
- 74 people
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
Chronic Obstructive Pulmonary Disease
Formoterol Certihaler, Tiotropium HandiHaler and Tiotropium HandiHaler in Combination With Formoterol Certihaler in Patients With Stable Chronic Obstructive Pulmonary Disease
This study is not being conducted in the United States. This study is designed to provide efficacy and safety data for formoterol 10µg twice-a-day (b.i.d.) delivered by the Certihaler in patients with chronic obstructive…
- Trial name
- NCT00134979
- Testing
- Formoterol
- Where
- Switzerland
- Volunteers
- 847 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This is a multicenter, randomized, double-blind, 3-way crossover study to evaluate the lung function response to UMEC 62.5 mcg, VI 25 mcg, and UMEC/VI 62.525 mcg, administered once-daily via a novel dry powder inhaler (NDPI) over…
- Trial name
- NCT02014480
- Testing
- Umeclidinium 62.5 mcg, Vilanterol 25 mcg, Umeclidinium/Vilanterol 62.5/25 mcg
- Where
- 21 sites in Slovakia, Ukraine
- Volunteers
- 207 people
- Sponsor
- GlaxoSmithKline
Pulmonary Function
Effects of Particulate Matter on the Pulmonary Function and Acute Exacerbation of COPD and Asthma
Particulate matter(PM) exposure has been shown to increase the morbidity and mobility of a variety of respiratory diseases, including COPD and asthma.
- Trial name
- NCT03193879
- Where
- China
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Pulmonary Disease, Chronic Obstructive
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL administered with 5 micrograms tiotropium bromide solution for inhalation, delivered by the Respimat inhaler, once daily for four weeks in…
- Trial name
- NCT00696020
- Testing
- BI 1744 CL/tiotropium bromide fixed dose combination, tiotropium bromide, Respimat® Inhaler
- Where
- 37 sites in United States, Canada and 1 more
- Volunteers
- 360 people
- Sponsor
- Boehringer Ingelheim
COPD
The Effect of QVAR on Lung Functioning in Chronic Obstructive Pulmonary Disease
This is an investigator-sponsored research study to evaluate if treatment with HFA-134a beclomethasone (QVAR) has an effect on peripheral (or outer) airway inflammation and airway "remodeling" or scarring in subjects with COPD.
- Trial name
- NCT00238082
- Testing
- HFA-134A Beclomethasone DIpropionate (QVAR)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Jewish Health
Heart Failure, Copd
Meals MATTER: A Trial of Medically Tailored Meals 2 Weeks vs. 4 Weeks Post Hospital Discharge
The purpose of this study is to determine if medically tailored meals provided for either 2 weeks or 4 weeks (1 meal per day) to a Kaiser Permanente Colorado (KPCO) member after hospital discharge will improve their health.
- Conditions
- Heart Failure, Copd, Liver Failure, Diabetes Mellitus
- Trial name
- NCT04351880
- Testing
- Medically Tailored Meals
- Where
- 2 sites in United States
- Volunteers
- 650 people
- Sponsor
- Kaiser Permanente
Pulmonary Disease, Chronic Obstructive
Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder Inhaler
The purpose of this study is to investigate 5 doses of RPL554 and placebo, administered by dry powder inhaler (DPI), in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT04027439
- Testing
- Part A: RPL554, Part B: RPL554
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Chronic Obstructive Pulmonary Disease
Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease
This will be an open-label, non-randomized multi-center study designed to assess the safety and efficacy of Adipose-derived Stem Cell (ASC) IV implantation.
- Trial name
- NCT02216630
- Testing
- Adipose Derived Stem Cell (ADSC) Therapy
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Kimera Society Inc
Malodorous Wounds (Chronic, Malignant or Infected Wounds)
Evaluation of the Quality of Life Induced by the Cinnamon Anti-odor Dressing in Patients With Malodorous Wounds
Refer to "Detailed description".
- Trial name
- CINNAMON (NCT05685628)
- Testing
- Cinnamon dressing, Charcoal dressing
- Where
- 7 sites in France
- Volunteers
- 98 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COPD
Impact of COPD on Muscle Regeneration
Muscle weakness and atrophy are important consequences of chronic obstructive pulmonary disease (COPD) and can affect both respiratory and peripheral muscles.
- Trial name
- NCT02557165
- Testing
- Muscle biopsies
- Volunteers
- 27 people
- Sponsor
- Laval University
COPD Exacerbation, Copd
nCD64 vs. Neutrophil/Lymphocyte Ratio for Predicting In-hospital Outcome in AE-COPD
Neutrophil CD64 versus Neutrophil/Lymphocyte ratio (NLR) as markers predicting in-hospital outcome in acute exacerbation of COPD
- Trial name
- NCT03146611
- Testing
- nCD64, Neutrophil/Lymphocyte Ratio
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- Assiut University
Pulmonary Disease, Chronic Obstructive
ADOAIR250 Anti-inflammatory Effects in Japanese Subjects With Chronic Obstructive Pulmonary Disease
The study will be conducted in a respiratory specialist institute in Japan, with standardized techniques and data assurance checks to optimize data quality.
- Trial name
- NCT01607398
- Testing
- ADOAIR250
- Where
- 3 sites in Japan
- Volunteers
- 56 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
Pulmonary and Cardiac Effects of E-Cigarette Use in Pulmonary Patients Who Smoke Cigarettes
The purpose of this study is to compare the effects of e-cigarettes and continued smoking on pulmonary and cardiac outcomes in a population with established pulmonary disease.
- Conditions
- Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema, Asthma-COPD Overlap Syndrome
- Trial name
- NCT05610514
- Testing
- E-Cigarette, Financial Incentives
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Vermont
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.